344 related articles for article (PubMed ID: 35992375)
1. Indole: A promising scaffold for the discovery and development of potential anti-tubercular agents.
Bajad NG; Singh SK; Singh SK; Singh TD; Singh M
Curr Res Pharmacol Drug Discov; 2022; 3():100119. PubMed ID: 35992375
[TBL] [Abstract][Full Text] [Related]
2. Indole Derivatives as Anti-Tubercular Agents: An Overview on their Synthesis and Biological Activities.
Reddy GS; Pal M
Curr Med Chem; 2021; 28(22):4531-4568. PubMed ID: 32951569
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review.
Dash S; Rathi E; Kumar A; Chawla K; Joseph A; Kini SG
J Biomol Struct Dyn; 2024 Aug; 42(12):6472-6522. PubMed ID: 37395797
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis.
Xiang W; He H; Duan X; He Z; Xu X; Liao M; Teng F; Li X; Luo T; Zeng J; Yu L; Gao C
Microbiol Spectr; 2023 Sep; 11(5):e0472122. PubMed ID: 37698416
[TBL] [Abstract][Full Text] [Related]
6. Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis.
Kb S; Kumari A; Shetty D; Fernandes E; Dv C; Jays J; Murahari M
J Mol Graph Model; 2020 Dec; 101():107718. PubMed ID: 32949960
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
[TBL] [Abstract][Full Text] [Related]
8. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.
Shirude PS; Shandil R; Sadler C; Naik M; Hosagrahara V; Hameed S; Shinde V; Bathula C; Humnabadkar V; Kumar N; Reddy J; Panduga V; Sharma S; Ambady A; Hegde N; Whiteaker J; McLaughlin RE; Gardner H; Madhavapeddi P; Ramachandran V; Kaur P; Narayan A; Guptha S; Awasthy D; Narayan C; Mahadevaswamy J; Vishwas KG; Ahuja V; Srivastava A; Prabhakar KR; Bharath S; Kale R; Ramaiah M; Choudhury NR; Sambandamurthy VK; Solapure S; Iyer PS; Narayanan S; Chatterji M
J Med Chem; 2013 Dec; 56(23):9701-8. PubMed ID: 24215368
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Structural Elucidation of Novel Benzothiazole Derivatives as Anti-tubercular Agents: In-silico Screening for Possible Target Identification.
Venugopala KN; Chandrashekharappa S; Pillay M; Bhandary S; Kandeel M; Mahomoodally FM; Morsy MA; Chopra D; Aldhubiab BE; Attimarad M; Alwassil OI; Harsha S; Mlisana K; Odhav B
Med Chem; 2019; 15(3):311-326. PubMed ID: 29968540
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.
Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C
Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793
[TBL] [Abstract][Full Text] [Related]
11. Ligand-protein interactions of plant-isolated (9z,12z)-octadeca-9,12-dienoic acid with Β-ketoacyl-Acp synthase (KasA) in potential anti-tubercular drug designing.
Mtewa AG; Bvunzawabaya JT; Ngwira KJ; Lampiao F; Maghembe R; Okella H; Weisheit A; Tolo CU; Ogwang PE; Sesaazi DC
Sci Afr; 2021 Jul; 12():e00824. PubMed ID: 37215382
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Anti-tubercular Modelling via QSAR Approach, In Silico Design and Virtual Docking Screening of Designed Hypothetical Inhibitors Against DNA gyrase Protein.
Adeniji SE
Curr Comput Aided Drug Des; 2021; 17(6):739-758. PubMed ID: 32586260
[TBL] [Abstract][Full Text] [Related]
14. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
Reddy DS; Kongot M; Kumar A
Tuberculosis (Edinb); 2021 Mar; 127():102050. PubMed ID: 33540334
[TBL] [Abstract][Full Text] [Related]
15. Decaprenylphosphoryl-β-D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis.
Crellin PK; Brammananth R; Coppel RL
PLoS One; 2011 Feb; 6(2):e16869. PubMed ID: 21346818
[TBL] [Abstract][Full Text] [Related]
16. A Review of the Therapeutic Importance of Indole Scaffold in Drug Discovery.
Teraiya N; Agrawal K; Patel TM; Patel A; Patel S; Shah U; Shah S; Rathod K; Patel K
Curr Drug Discov Technol; 2023; 20(6):9-37. PubMed ID: 37151073
[TBL] [Abstract][Full Text] [Related]
17. Easily accessed nitroquinolones exhibiting potent and selective anti-tubercular activity.
Dube PS; Legoabe LJ; Jordaan A; Jesumoroti OJ; Tshiwawa T; Warner DF; Beteck RM
Eur J Med Chem; 2021 Mar; 213():113207. PubMed ID: 33524688
[TBL] [Abstract][Full Text] [Related]
18. Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.
Manina G; Pasca MR; Buroni S; De Rossi E; Riccardi G
Curr Med Chem; 2010; 17(27):3099-108. PubMed ID: 20629622
[TBL] [Abstract][Full Text] [Related]
19. Chemical Space Exploration of DprE1 Inhibitors Using Chemoinformatics and Artificial Intelligence.
Chhabra S; Kumar S; Parkesh R
ACS Omega; 2021 Jun; 6(22):14430-14441. PubMed ID: 34124465
[TBL] [Abstract][Full Text] [Related]
20. Recent advances of imidazole-containing derivatives as anti-tubercular agents.
Fan YL; Jin XH; Huang ZP; Yu HF; Zeng ZG; Gao T; Feng LS
Eur J Med Chem; 2018 Apr; 150():347-365. PubMed ID: 29544148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
